Celsion Corporation (NASDAQ:CLSN) Files An 8-K Entry into a Material Definitive Agreement

Celsion Corporation (NASDAQ:CLSN) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01

to the Purchase Agreement, the Company and Aspire Capital terminated the prior Common Stock Purchase Agreement, dated August 31, 2018, between the parties.

The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02 in its entirety.

(d) Exhibits

Common Stock Purchase Agreement, dated October 28, 2019 between Celsion Corporation and Aspire Capital Fund, LLC *
*Filed herewith.


Celsion CORP Exhibit
EX-4.1 2 ex4-1.htm   REGISTRATION RIGHTS AGREEMENT   REGISTRATION RIGHTS AGREEMENT (this “Agreement”),…
To view the full exhibit click here

Story continues below

About Celsion Corporation (NASDAQ:CLSN)

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

An ad to help with our costs